Equity Overview
Price & Market Data
Price: $33.06
Daily Change: +$0.26 / 0.79%
Daily Range: $32.95 - $33.08
Market Cap: $2,195,222,016
Daily Volume: 1,300
Performance Metrics
1 Week: -1.41%
1 Month: 13.85%
3 Months: 24.86%
6 Months: 44.56%
1 Year: 28.53%
YTD: 19.27%
Company Details
Employees: 704
Sector: Health technology
Industry: Biotechnology
Country:
Details
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.